The World Health Organization (WHO) has released its first dedicated guidelines on the diagnosis and management of type 1 diabetes in adults, marking an important development in global diabetes care.

Announced on November 14, 2026, to coincide with World Diabetes Day, the guidelines aim to help healthcare professionals provide safe, effective, and accessible treatment across different healthcare settings.

The new WHO type 1 diabetes guidelines 2026 place particular emphasis on insulin therapy, blood glucose monitoring, early diagnosis, and access to essential treatment.

They also address the needs of people living in low-resource, emergency, and humanitarian settings, where obtaining regular insulin supplies and medical support can be especially challenging.

Why Has WHO Introduced New Type 1 Diabetes Guidelines?

Type 1 diabetes is a lifelong condition in which the body produces little or no insulin.

Insulin is a hormone that allows glucose to move from the bloodstream into the body’s cells, where it can be used for energy.

Without sufficient insulin, blood glucose can rise to dangerous levels.

People with type 1 diabetes require insulin treatment to survive.

Despite the discovery of insulin more than a century ago, access to affordable insulin and reliable blood glucose monitoring remains unequal worldwide.

WHO developed the guidelines to help healthcare systems provide consistent, evidence-based treatment, including in places with limited resources.

How Many People Have Type 1 Diabetes Worldwide?

According to WHO’s November 2026 announcement, approximately 9.5 million people worldwide were living with type 1 diabetes in 2025.

An estimated 500,000 people were newly diagnosed during that year.

Although type 1 diabetes is often associated with childhood, it can develop at any age.

Adults may experience delayed diagnosis or initially be thought to have another form of diabetes.

Recognising symptoms and confirming the correct diagnosis are important steps toward timely treatment.

Key Recommendations in the WHO Type 1 Diabetes Guidelines 2026

The guidelines address several essential aspects of diabetes care.

1. Multiple Daily Insulin Injections

WHO strongly recommends intensified insulin therapy using multiple daily injections, with doses adjusted according to blood glucose measurements.

The goal is to help people manage glucose levels while reducing the risk of serious complications.

Insulin regimens must be individualised by qualified healthcare professionals.

Patients should never change or stop prescribed insulin treatment based solely on general health information.

2. Human Insulin Remains an Effective Option

The guidelines recognise human insulin as an effective treatment option.

Human insulin is manufactured to work like insulin naturally produced by the body.

WHO notes that human insulin is generally less expensive than some insulin analogues, making it an important option where affordability is a concern.

Insulin analogues may also be used when clinically appropriate.

The best choice depends on individual needs, treatment availability, and professional assessment.

3. Regular Blood Glucose Monitoring

Monitoring blood glucose is essential for managing type 1 diabetes.

WHO recommends regular assessment of glucose levels using suitable methods.

These may include:

HbA1c provides information about average blood glucose levels over approximately the previous two to three months.

Continuous glucose monitoring uses a sensor to track glucose levels throughout the day and night.

Where blood glucose testing is unavailable, WHO notes that urine glucose testing may be considered as a limited alternative.

However, urine testing does not provide the same information as blood glucose monitoring.

4. Individualised Diabetes Care

People living with type 1 diabetes have different medical needs, lifestyles, and access to healthcare resources.

Treatment should consider factors such as:

Healthcare professionals should work with patients to develop realistic, safe management plans.

5. Support for Emergency and Humanitarian Settings

One important feature of the new WHO guidance is its focus on healthcare delivery during emergencies.

People with type 1 diabetes may face life-threatening risks when conflict, displacement, disasters, or supply disruptions interrupt insulin access.

WHO recommends practical approaches that help maintain continuity of insulin treatment and monitoring in these circumstances.

This includes considering available insulin types and adapting care to local resources.

What Are the Symptoms of Type 1 Diabetes?

Type 1 diabetes symptoms may develop rapidly.

Common warning signs include:

Some people may also experience nausea, vomiting, abdominal pain, or unusual breathing.

These symptoms can indicate diabetic ketoacidosis, a potentially life-threatening emergency.

Seek emergency medical care immediately if diabetes symptoms are accompanied by vomiting, deep or rapid breathing, confusion, severe weakness, or fruity-smelling breath.

Early diagnosis and treatment can prevent serious complications.

Type 1 Diabetes vs. Type 2 Diabetes

Although both conditions involve elevated blood glucose, they have important differences.

FeatureType 1 DiabetesType 2 Diabetes
Main mechanismAutoimmune destruction of insulin-producing cells in most casesInsulin resistance and progressive insulin-production problems
Typical onsetCan occur at any ageMore common in adults, but can occur at any age
Insulin treatmentRequired for survivalRequired for some people
PreventionNo established general prevention methodSome cases can be prevented or delayed
ManagementInsulin, monitoring, education and ongoing careLifestyle support, medication, monitoring and sometimes insulin

Correctly identifying the type of diabetes helps clinicians select appropriate treatment.

Why Insulin Access Is a Global Health Priority

Insulin is essential for people with type 1 diabetes.

However, affordability, availability, and healthcare infrastructure remain significant barriers in many countries.

Some patients face difficulties obtaining insulin, testing supplies, or regular clinical follow-up.

WHO’s guidelines support the global goal of ensuring that all people with type 1 diabetes have access to affordable insulin and blood glucose self-monitoring by 2030.

Achieving this goal will require cooperation among governments, healthcare providers, manufacturers, and public health organisations.

How Technology Supports Diabetes Management

Modern diabetes technology can make glucose monitoring and insulin delivery more convenient for some patients.

Continuous Glucose Monitors

Continuous glucose monitors use small sensors to provide regular glucose readings.

They can help users and clinicians recognise glucose patterns and identify periods of high or low blood sugar.

Insulin Pumps

Insulin pumps deliver insulin through a small device.

They may be appropriate for some patients, depending on clinical needs, training, and availability.

Automated Insulin Delivery Systems

Some systems combine glucose sensors with insulin pumps and software that adjusts insulin delivery.

These technologies can be useful but are not available or suitable for everyone.

WHO’s 2026 guidelines emphasise approaches that can work across healthcare settings, including those where advanced technology is unavailable.

Preventing Diabetes Complications

Consistent diabetes management can reduce the risk of complications.

Poorly controlled blood glucose over time can contribute to damage affecting the eyes, kidneys, nerves, heart, and blood vessels.

Important aspects of ongoing care include:

Regular care is important even when a person feels well.

The Importance of Diabetes Education

Living with type 1 diabetes requires daily decisions about food, physical activity, insulin, and glucose monitoring.

Diabetes education helps patients understand how these factors interact.

Education may cover recognising hypoglycaemia, managing illness, storing insulin, responding to glucose readings, and knowing when to seek medical help.

Support from healthcare professionals, family members, and diabetes communities can also improve confidence in day-to-day management.

What Do the Guidelines Mean for Developing Countries?

The new guidance may be particularly relevant for countries where access to specialist diabetes care is limited.

In some settings, patients may depend on primary healthcare providers for diagnosis and treatment.

WHO’s recommendations provide a framework for delivering essential care without assuming that every clinic has advanced technology.

The emphasis on affordable human insulin and practical monitoring options may help healthcare systems design more accessible services.

However, publishing guidelines alone will not resolve supply shortages, healthcare costs, or workforce limitations.

Implementation will require sustained investment and monitoring.

World Diabetes Day 2026: Early Action on Diabetes

The theme of World Diabetes Day 2026 is Early Action on Diabetes.

The campaign highlights the importance of recognising symptoms, improving diagnosis, and ensuring timely access to appropriate care.

WHO has also emphasised the need to reduce diabetes-related stigma.

People living with diabetes deserve accurate information, respectful treatment, and support without blame.

What Should People Living With Type 1 Diabetes Do?

The new guidelines do not mean that everyone needs to change their current insulin regimen.

People already receiving treatment should continue following their prescribed care plans unless their healthcare professional recommends adjustments.

Useful questions to discuss at a medical appointment include:

Individualised medical advice remains essential.

Conclusion

The release of the WHO type 1 diabetes guidelines 2026 represents a significant step toward improving access to evidence-based diabetes care worldwide.

The recommendations emphasise multiple daily insulin injections, appropriate insulin selection, regular glucose monitoring, and individualised treatment.

Importantly, they also recognise the challenges faced by people living in low-resource and emergency settings.

As countries work toward the 2030 goal of universal access to affordable insulin and glucose self-monitoring for people with type 1 diabetes, the new guidance offers a framework for more equitable care.

Early diagnosis, reliable treatment, education, and ongoing medical support remain essential for helping people with type 1 diabetes live healthy lives.

Frequently Asked Questions

What are the WHO type 1 diabetes guidelines for 2026?

They are evidence-based recommendations covering diagnosis, insulin treatment, glucose monitoring, and care for adults with type 1 diabetes, including in low-resource and emergency settings.

When were the guidelines announced?

WHO announced the new adult guidelines on November 14, 2026, during World Diabetes Day.

Does WHO recommend insulin for type 1 diabetes?

Yes. Insulin is essential for people with type 1 diabetes. The guidelines strongly recommend intensified insulin therapy with doses adjusted according to blood glucose measurements.

Can adults develop type 1 diabetes?

Yes. Type 1 diabetes can develop at any age, including adulthood.

Is human insulin effective for type 1 diabetes?

Yes. WHO recognises human insulin as an effective treatment option and notes its affordability advantages in many settings.

Can type 1 diabetes be cured?

There is currently no established cure for type 1 diabetes. Ongoing insulin treatment and monitoring are essential.

What is the WHO diabetes goal for 2030?

One target is to ensure that 100% of people with type 1 diabetes have access to affordable insulin treatment and blood glucose self-monitoring.


References

  1. World Health Organization – WHO Issues First Guidelines on Type 1 Diabetes for Adults, November 14, 2026
  2. WHO – Guidelines on Insulin Use for Type 1 Diabetes in Adults, November 12, 2026
  3. WHO – World Diabetes Day 2026
  4. WHO – Diabetes Overview

Medical disclaimer: This article is for educational and news-reporting purposes. It does not replace professional medical advice. People using insulin should not change doses or stop treatment without guidance from their healthcare team.

Leave a Reply

Your email address will not be published. Required fields are marked *

Secret Link